natgillin/translations-raw huggingface dataset:
What Atazanavir Krka contains - The active substance is atazanavir. 
Kaj vsebuje zdravilo Atazanavir Krka - Učinkovina je atazanavir.
Raltegravir AUC ↑41% Raltegravir cmax ↑24% Raltegravir c12hr ↑77% The mechanism is UGT1A1 inhibition. 
Raltegravir AUC ↑41 % Raltegravir Cmax ↑24 % Raltegravir C12hr ↑77 %
De novo substitutions in treatment naive patients failing therapy with atazanavir + ritonavir (Study 138, 96 weeks) 
Preglednica 3: Pojav novih substitucij pri predhodno še nezdravljenih bolnikih po neuspešnem zdravljenju z atazanavirjem + ritonavirjem (študija 138, 96 tednov) Pogostnost
Three of 20 infants (15%) born to women treated with atazanavir /ritonavir 300/100 mg and four of 20 infants (20%) born to women treated with atazanavir /ritonavir 400/100 mg experienced grade 3-4 bilirubin. 
Pri treh od 20 dojenčkov (15 %) katerih matere so se zdravile z atazanavirjem/ritonavirjem v odmerku 300/100 mg in pri štirih od 20 dojenčkov (20 %), ki so se rodili materam, ki so se zdravile z atazanavirjem/ritonavirjem v odmerku 400/100 mg, so poročali o vrednosti bilirubina stopnje 3-4.
Study 138 is an international randomised, open-label, multicenter, prospective trial of treatment naïve patients comparing atazanavir /ritonavir (300 mg/100 mg once daily) to lopinavir/ritonavir (400 mg/100 mg twice daily), each in combination with fixed dose tenofovir disoproxil fumarate/emtricitabine (300 mg/200 mg tablets once daily). 
Študija 138 je mednarodno, randomizirano, odprto, multicentrično, prospektivno preskušanje, ki je pri predhodno še nezdravljenih bolnikih primerjalo uporabo atazanavirja/ritonavirja (300 mg/100 mg enkrat na dan) z uporabo lopinavirja/ritonavirja (400 mg/100 mg dvakrat na dan), oboje v kombinaciji s fiksnimi odmerki dizoproksiltenofovirjevega fumarata/emtricitabina (300 mg/200 mg tablete enkrat na dan).
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occurs many months after initiation of treatment. 
Poročajo, da se med imunsko reaktivacijo lahko pojavijo tudi avtoimunske bolezni (kot je Gravesova bolezen); čas do njihovega nastanka je spremenljiv, zato se lahko pojavijo tudi več mesecev po začetku zdravljenja.
In a clinical study AI424-020, paediatric patients 3 months to less than 18 years of age who received either the oral powder or capsule formulation had a mean duration of treatment with atazanavir of 115 weeks. 
V klinični študiji AI424-020 je zdravljenje pediatričnih bolnikov, starih od 3 mesecev do manj kot 18 let, z atazanavirjem v obliki peroralnega praška ali kapsul v povprečju trajalo 115 tednov.
≥ 200 cells/mm 
≥ 200 celic/mm3
Patients co-infected with hepatitis B and/or hepatitis C virus Among 1,151 patients receiving atazanavir 400 mg once daily, 177 patients were co-infected with chronic hepatitis B or C, and among 655 patients receiving atazanavir 300 mg once daily with ritonavir 100 mg once daily, 97 patients were co-infected with chronic hepatitis B or C. Coinfected patients were more likely to have baseline hepatic transaminase elevations than those without chronic viral hepatitis. 
Bolniki, sočasno okuženi z virusom hepatitisa B in/ali hepatitisa C Od 1.151 bolnikov, ki so prejemali atazanavir v odmerku 400 mg enkrat na dan, je 177 bolnikov sočasno imelo kronični hepatitis B ali C. Od 655 bolnikov, ki so prejemali atazanavir v odmerku 300
When compared to atazanavir 300 mg with ritonavir 100 mg without tenofovir disoproxil, atazanavir concentrations are expected to be additionally decreased by about 
Pri uporabi atazanavirja v odmerku 300 mg in ritonavirja v odmerku 100 mg brez dizoproksiltenofovirjevega fumarata pa pričakujemo, da se bodo koncentracije atazanavirja še dodatno zmanjšale za približno 20%.
It is especially important to mention these: - other medicines to treat HIV infection (e.g. indinavir, nevirapine and efavirenz) - boceprevir and sofosbuvir/velpatasvir/voxilaprevir (used to treat hepatitis C) - sildenafil, vardenafil, or tadalafil (used by men to treat impotence (erectile dysfunction)) - if you are taking an oral contraceptive ("the Pill") with Atazanavir Krka to prevent pregnancy, 
Posebno pomembno je omeniti naslednje: - druga zdravila za zdravljenje okužbe z virusom HIV (npr. indinavir, nevirapin in efavirenz), - boceprevir (zdravilo za zdravljenje hepatitisa C), - sildenafil, vardenafil ali tadalafil (zdravila za zdravljenje moške impotence (erektilna disfunkcija)),
If you take more Atazanavir Krka than you should Yellowing of the skin and/or eyes (jaundice) and irregular heart beat (QTc prolongation) may occur if you or your child take too much Atazanavir Krka. 
Če ste vzeli večji odmerek zdravila Atazanavir Krka, kot bi smeli Če ste vzeli ali je otrok vzel prevelik odmerek zdravila Atazanavir Krka, se lahko pojavi rumeno obarvanje kože in/ali očesnih beločnic (zlatenica) in nepravilen srčni utrip (podaljšanje intervala QTc).
ACID REDUCING AGENTS 
ZDRAVILA ZA ZMANJŠEVANJE KISLOSTI ŽELODČNEGA SOKA
Two percent of patients treated with atazanavir experienced concurrent Grade 3-4 ALT/AST and Grade 3-4 total bilirubin elevations. 
Dva odstotka bolnikov, ki so prejemali atazanavir, sta imela sočasno zvišanje ALT/AST 3. oz. 4.
Overall in this study, 182 paediatric patients (81 antiretroviral-naive and 101 antiretroviral-experienced) received once daily atazanavir (capsule or powder formulation), with or without ritonavir, in combination with two NRTIs. 
(81 jih še ni prejemalo protiretrovirusnih zdravil, 101 bolnik pa je protiretrovirusna zdravila že jemal) prejemalo atazanavir enkrat na dan (v obliki kapsul ali praška), z ritonavirjem ali brez njega, v kombinaciji z dvema NRTI-jema.
For treatmentexperienced paediatric patients, the mean baseline CD4 cell count was 522 cells/mm3 (range: 100 to 
Pri bolnikih, ki so predhodno že prejemali tovrstno zdravljenje, je bilo v izhodišču srednje število celic CD4 522 celic/mm3 (razpon: 100 do
Do not take sildenafil with Atazanavir Krka when sildenafil is used for the treatment of pulmonary arterial hypertension. 
Med zdravljenjem z zdravilom Atazanavir Krka ne smete uporabljati sildenafila za zdravljenje pljučne arterijske hipertenzije.
Atazanavir Krka 150 mg hard capsules Atazanavir Krka 200 mg hard capsules Atazanavir Krka 300 mg hard capsules atazanavir 
Atazanavir Krka 150 mg trde kapsule Atazanavir Krka 200 mg trde kapsule Atazanavir Krka 300 mg trde kapsule
Electrocardiographic changes (sinus bradycardia, prolongation of PR interval, prolongation of QT interval, and prolongation of QRS complex) were observed only in an initial 2 week oral toxicity study performed in dogs. 
Elektrokardiografske spremembe (sinusna bradikardija, podaljšanje intervala PR, intervala QT in razširitev kompleksa
Co-administration with atazanavir may cause a large increase in the concentration of these benzodiazepines. 
Pri sočasni uporabi atazanavirja se lahko koncentracije teh benzodiazepinov močno povečajo.
PDE5 inhibitors used for the treatment of erectile dysfunction: particular caution should be used when prescribing PDE5-inhibitors (sildenafil, tadalafil, or vardenafil) for the treatment of erectile dysfunction in patients receiving Atazanavir Krka. 
Uporaba zaviralcev PDE5 za zdravljenje erektilne disfunkcije: pri bolnikih, ki se zdravijo z zdravilom Atazanavir Krka, je potrebna posebna previdnost pri predpisovanju zaviralcev PDE5 (sildenafil,
The geometric mean (CV%) for atazanavir cmin and AUC was 654 (76%) ng/ml and 44185 (51%) ng•h/ml, respectively. 
Geometrijska srednja vrednost Cmin (KV %) atazanavirja je bila 654 (76 %) ng/ml, geometrijska srednja vrednost AUC (KV %) atazanavirja pa 44.185 (51 %) ng•h/ml.
At baseline, 34% of patients were receiving a PI and 60% were receiving an NNRTI. 
Izhodiščno je 34 % bolnikov dobivalo zaviralce proteaz in 60 % NNRTI-je.
Week 48: -3% [-7.6%, 1.5%] Week 96: 2.2% [-2.3%, 6.7%] HIV RNA <50 copies/ml, % by Baseline Characteristic d 
48. teden: -3 % [-7,6 %, 1,5 %] 96. teden: 2,2 % [-2,3 %, 6,7 %]
MARKETING AUTHORISATION NUMBER(S) EU/1/19/1353/001 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/19/1353/001
LIST OF EXCIPIENTS Contains also lactose monohydrate. 
Vsebuje tudi laktozo monohidrat.
The capsule cap is imprinted with black mark A150. 
Na kapici kapsule je odtisnjena črna oznaka A150.
If you stop taking Atazanavir Krka Do not stop taking Atazanavir Krka before talking to your doctor. 
Zdravila Atazanavir Krka ne smete prenehati jemati, dokler se ne posvetujete z zdravnikom.
Coadministration of diltiazem and atazanavir /ritonavir has not been studied. 
Sočasne uporabe diltiazema in atazanavirja/ritonavirja niso raziskovali.
Atazanavir (am): 2 hr after omeprazole 
Atazanavir (dopoldan): 2 uri po omeprazolu
The 24 hour concentration following a high fat meal was increased by approximately 33% due to delayed absorption; the median Tmax increased from 2.0 to 5.0 hours. 
33 %; srednji čas Tmax se je podaljšal iz 2,0 na 5,0 ur.
If you forget to take Atazanavir Krka 
Če ste pozabili vzeti zdravilo Atazanavir Krka
The geometric mean (CV%) for atazanavir cmin and AUC were 120 (109) ng/ml and 14874 (91) ng•h/ml, respectively. 
Geometrijska srednja vrednost Cmin (KV %) atazanavirja je znašala 120 (109) ng/ml, geometrijska srednja vrednost AUC (KV %) atazanavirja pa 14.874 (91) ng•h/ml.
Method of administration For oral use. 
Način uporabe Peroralna uporaba.
Among patients who received atazanavir 400 mg once daily or atazanavir 300 mg with ritonavir 100 mg once daily, the only adverse reactions of any severity reported very commonly with at least a possible relationship to regimens containing atazanavir and one or more NRTIs were nausea (20%), diarrhoea (10%), and jaundice (13%). 
Pri bolnikih, ki so prejemali atazanavir v odmerku 400 mg enkrat na dan ali atazanavir v odmerku 300 mg skupaj z ritonavirjem v odmerku 100 mg enkrat na dan, so bili kot zelo pogosti opisani le naslednji neželeni učinki vseh jakosti, ki bi vsaj lahko bili povezani z uporabo atazanavirja v kombinaciji z enim NRTI-jem ali več NRTI-ji: slabost (20 %), driska (10 %) in zlatenica (13 %).
MARKETING AUTHORISATION NUMBER(S) EU/1/19/1353/002 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/19/1353/002
Voriconazole AUC ↑561% Voriconazole cmax ↑438% (↑355% Voriconazole cmin ↑765% (↑571% 
Vorikonazol AUC ↑561 % (↑451 % Vorikonazol Cmax ↑438 % (↑355 % Vorikonazol Cmin ↑765 % (↑571 %
Co-administration of atazanavir/ritonavir and these glucocorticoids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects (see section 4.4). 
Sočasne uporabe atazanavirja/ritonavirja in teh glukokortikoidov ne priporočamo, razen če možne koristi zdravljenja prevladajo nad tveganjem za pojav sistemskih kortikosteroidnih učinkov (glejte poglavje 4.4).
Protease inhibitors: The co-administration of atazanavir /ritonavir and other protease inhibitors has not been studied but would be expected to increase exposure to other protease inhibitors. 
Zaviralci proteaz: Sočasne uporabe atazanavirja/ritonavirja in drugih zaviralcev proteaz niso raziskovali.
H2-Receptor antagonists Without Tenofovir disoproxil In HIV-infected patients with atazanavir/ritonavir at the recommended dose 300/100 mg once daily 
Brez dizoproksiltenofovirata Pri z virusom HIV okuženih bolnikih, ki so se zdravili z atazanavirjem/ritonavirjem v priporočenem odmerku 300/100 mg enkrat na dan
Co-administration of a single 300 mg dose of atazanavir and 100 mg dose of ritonavir with a light meal resulted in a 33% increase in the AUC and a 40% increase in both the cmax and the 24 hour concentration of atazanavir relative to the fasting state. 
V primerjavi z uporabo na tešče so se pri uporabi enkratnega 300 mg odmerka atazanavirja in 100 mg odmerka ritonavirja skupaj z lahkim obrokom vrednosti AUC, Cmax in 24-urne koncentracije atazanavirja povečale, in sicer AUC za 33 %, Cmax in 24-urna koncentracija pa za 40 %.
Lamotrigine should be used with caution in combination with atazanavir /ritonavir. 
Lamotrigin je treba v kombinaciji z atazanavirjem/ritonavir uporabljati previdno.
* In a combined analysis from several clinical studies, atazanavir/ritonavir 300/100 mg co-administered with tenofovir disoproxil fumarate 300 mg (n=39) was compared to atazanavir/ritonavir 300/100 mg (n=33). 
* Kombinirana analiza več kliničnih študij, v katerih so uporabo atazanavirja/ritonavirja 300/100 mg skupaj z dizoproksiltenofovirjevim fumaratom v odmerku 300 mg (n = 39) primerjali z uporabo atazanavirja/ritonavirja 300/100 mg (n =
Co-administration of atazanavir with grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination is contraindicated because of the increase in grazoprevir and elbasvir plasma concentrations and potential for the increase in risk of ALT elevations associated with increased grazoprevir concentrations (see section 4.3). 
Sočasna uporaba atazanavirja in zdravil, ki vsebujejo grazoprevir, vključno s fiksno kombinacijo elbasvir/grazoprevir, je kontraindicirana zaradi povečanja koncentracij grazoprevirja in elbasvirja v plazmi in možnega večjega tveganja za zvišanje vrednosti ALT, povezanega s povečanimi koncentracijami grazoprevirja (glejte poglavje 4.3).
Phenobarbital and phenytoin should be used with caution in combination with atazanavir /ritonavir. 
Fenobarbital in fenitoin je treba v kombinaciji z atazanavirjem/ritonavir uporabljati previdno.
Some medicines may interact with ritonavir, a medicine that is taken with Atazanavir Krka. 
Nekatera zdravila lahko vplivajo na delovanje ritonavirja, zdravila, ki se jemlje skupaj z zdravilom
The capsule cap is imprinted with white mark A300. 
Na kapici kapsule je odtisnjena bela oznaka A300.
When co-administered with tenofovir disoproxil fumarate, it is recommended that atazanavir 300 mg be given with ritonavir 100 mg and tenofovir disoproxil fumarate 300 mg (all as a single dose with food). 
Pri sočasni uporabi dizoproksiltenofovirjevega fumarata je priporočljivo atazanavir v odmerku 300 mg uporabljati skupaj z ritonavirjem v odmerku 100 mg in dizoproksiltenofovirjevim fumaratom v odmerku 300 mg (vse v obliki enkratnega odmerka skupaj s hrano).
Clarithromycin AUC ↑94% (↑75% Clarithromycin cmax ↑50% (↑32% Clarithromycin cmin ↑160% 
Klaritromicin AUC ↑94 % (↑75 % Klaritromicin Cmax ↑50 % (↑32 % ↑71 %) Klaritromicin Cmin ↑160 % (↑135 %
Children receiving Atazanavir Krka may require their heart to be monitored. 
Pri otrocih, ki prejemajo zdravilo Atazanavir Krka, bo morda treba spremljati delovanje srca, o čemer se bo odločil otrokov zdravnik.
a The mean baseline CD4 cell count was 337 cells/mm3 (range: 14 to 1,543 cells/mm3) and the mean baseline plasma HIV-1 
a Srednje število celic CD4 v izhodišču je bilo 337 celic/mm3 (razpon od 14 do 1.543 celic/mm3), srednja vrednost plazemske
The proportion of patients with HIV RNA < 400 copies/ml were 53% and 43% for ATV/RTV and 54% and 46% for LPV/RTV at weeks 48 and 96 respectively. 
V 96. tednu je bil delež bolnikov s HIV RNA < 400 kopij/ml pri kombinaciji ATV/RTV 43 %, pri kombinaciji LPV/RTV pa 46 %.
Atazanavir Krka 150 mg and 200 mg hard capsules are available in containers containing 60 hard capsules; in a box. 
Zdravilo Atazanavir Krka 150 mg in 200 mg je na voljo v vsebnikih po 60 trdih kapsul; v škatli.
Therefore, Atazanavir Krka is contraindicated with medicinal products that are substrates of CYP3A4 and have a narrow therapeutic index: quetiapine, lurasidone, alfuzosin, astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil, triazolam, orally administered midazolam, and ergot alkaloids, particularly ergotamine and dihydroergotamine (see section 4.3). 
Zdravilo Atazanavir Krka se ne sme uporabljati skupaj z zdravili, ki so substrat za CYP3A4 in imajo ozek terapevtski indeks, npr. kvetiapin, lurasidon, alfuzosin, astemizol, terfenadin, cisaprid, pimozid, kinidin, bepridil, triazolam, peroralne oblike midazolama in alkaloidi ergot, zlasti ergotamin in dihidroergotamin (glejte poglavje 4.3).
Talk to your doctor or pharmacist before taking Atazanavir Krka and make sure your doctor knows: - if you have hepatitis B or C - if you develop signs or symptoms of gall stones (pain at the right side of your stomach) - if you have type A or B haemophilia - if you require haemodialysis 
- če imate hepatitis B ali C, - če se pojavijo znaki ali simptomi žolčnih kamnov (bolečina v desnem predelu trebuha), - če imate hemofilijo tipa A ali B,
Some people will need special care before or while taking Atazanavir Krka. 
Nekateri ljudje morajo biti posebej previdni pri jemanju zdravila Atazanavir Krka.
Didanosine (with food) Didanosine AUC ↓34% (↓41% ↓27%) Didanosine cmax ↓38% (↓48% ↓26%) Didanosine cmin 
Didanozin (s hrano) Didanozin AUC ↓34 % (↓41 % ↓27 %) Didanozin Cmax ↓38 % (↓48 % ↓26 %) Didanozin Cmin ↑25 % (↓8 % ↑69 %)
RNA level was 4.4 log10 copies/ml (range: 2.6 to 5.88 log10 copies/ml). 
HIV-1 RNA v izhodišču pa 4,4 log10 kopij/ml (razpon od 2,6 do 5,88 log10 kopij/ml).
Additional minor metabolic pathways consist of N-dealkylation and hydrolysis. 
Dodatna manj pomembna metabolna pot obsega N
Hepatic transaminase elevations that occur with elevated bilirubin in patients receiving atazanavir should be evaluated for alternative aetiologies. 
Če se pri bolniku, ki se zdravi z atazanavirjem, pojavi zvišanje vrednosti jetrnih transaminaz, ki jih spremlja zvišanje vrednosti bilirubina, je treba ugotoviti morebiten alternativni vzrok.
Ketoconazole and itraconazole should be used cautiously with atazanavir /ritonavir, high doses of ketoconazole and itraconazole (>200 mg/day) are not recommended. 
Uporaba visokih odmerkov ketokonazola in itrakonazola (> 200 mg/dan) ni priporočljiva.
Unboosted Atazanavir Krka must not be used in patients with severe hepatic impairment. 
Atazanavir Krka brez okrepitve farmakokinetike se ne sme uporabljati pri bolnikih s hudo okvaro jeter.
By as-treated analysis, excluding missing values, the proportions of patients with HIV RNA <400 copies/ml (<50 copies/ml) for atazanavir + ritonavir were 84% (72%) and for lopinavir + ritonavir were 82% (72%). 
kopij/ml (< 50 kopij/ml) za atazanavir + ritonavir 84 % (72 %) in za lopinavir + ritonavir 82 % (72 %).
HIV RNA <50 copies/ml, %f (responder/evaluable) All patients 
HIV RNA < 50 kopij/ml, %f (bolniki z odzivom/ovrednosteno) Vsi bolniki
- Yellowing of your skin or the white part of your eyes caused by high levels of bilirrubin in your blood has been commonly reported. 
- Pogosto so poročali o rumenem obarvanju kože ali očesnih beločnic, ki je posledica visokih vrednosti bilirubina v krvi.
Atazanavir (am): 1 hr after omeprazole 
Atazanavir (dopoldan): 1 uro po omeprazolu
Nevirapine AUC ↑26% (↑17% Nevirapine cmax ↑21% (↑11% Nevirapine cmin ↑35% (↑25% 
Nevirapin AUC ↑26 % (↑17 % ↑36 %) Nevirapin Cmax ↑21 % (↑11 % ↑32 %) Nevirapin Cmin ↑35 % (↑25 % ↑47 %)
- medicines containing St. John's wort (Hypericum perforatum, a herbal preparation) - triazolam and oral (taken by mouth) midazolam (used to help you sleep and/or to relieve anxiety) - simvastatin and lovastatin (used to lower blood cholesterol). 
- pripravki, ki vsebujejo šentjanževko (Hypericum perforatum, zdravilo rastlinskega izvora), - triazolam in peroralne oblike (ki se jemljejo skozi usta) midazolama (uporabljamo jih kot pomoč pri težavah s spanjem in/ali za ublažitev tesnobe),
If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment. 
Če opazite kakršne koli simptome okužbe ali druge simptome, na primer mišično oslabelost, oslabelost, ki se najprej pojavi v dlaneh in stopalih in nato širi proti trupu,
Co-administration of Atazanavir Krka and medicinal products that induce CYP3A4 is not recommended (see sections 4.3 and 4.5). 
Zdravila Atazanavir Krka ni priporočljivo uporabljati skupaj z zdravili, ki inducirajo CYP3A4 (glejte poglavji 4.3 in 4.5).
While the concentration of ethinyloestradiol was increased with atazanavir given alone, due to both UGT and CYP3A4 inhibition by atazanavir, the net effect of atazanavir/ritonavir is a decrease in ethinyloestradiol levels because of the inducing effect of ritonavir. 
UGT in CYP3A4 so se koncentracije etinilestradiola pri uporabi atazanavirja samega povečale, vendar pa so se zaradi inducirajočega učinka ritonavirja pri uporabi atazanavirja/ritonavirja vrednosti etinilestradiola zmanjšale.
* When compared to atazanavir 300 mg and ritonavir 100 mg without nevirapine. 
• Pri primerjavi atazanavirja v odmerku 300 mg in ritonavirja v odmerku 100 mg brez nevirapina.
Metabolism and nutrition disorders uncommon: weight decreased, weight gain, anorexia, appetite increased 
občasni: zmanjšanje telesne mase, povečanje telesne mase, anoreksija, povečan apetit
The recommended dose of Atazanavir Krka capsules is 300 mg once daily taken with ritonavir 100 mg once daily and with food. 
Priporočeni odmerek zdravila Atazanavir Krka je 300 mg enkrat na dan skupaj z ritonavirjem v odmerku 100 mg enkrat na dan in skupaj s hrano.
Methadone, stable maintenance dose 
Buprenorfin, enkrat na dan, stabilni vzdrževalni odmerek
Atazanavir inhibits UGT and may interfere with the metabolism of irinotecan, resulting in increased irinotecan toxicities. 
Atazanavir zavira UGT in lahko vpliva na presnovo irinotekana, pri čemer se
Studies conducted in HIV- infected patients. 
Študije, izvedene pri bolnikih, okuženih z virusom HIV.
Co-administration of Atazanavir Krka with nevirapine or efavirenz is not recommended (see section 4.5). 
Sočasna uporaba zdravila Atazanavir Krka in nevirapina ali efavirenza ni priporočljiva (glejte poglavje 4.5).
Norgestimate AUC ↑85% (↑67% Norgestimate cmax ↑68% (↑51% Norgestimate cmin ↑102% (↑77% 
Norgestimat AUC ↑85 % (↑67 % ↑105 %) Norgestimat Cmax ↑68 % (↑51 % ↑88 %) Norgestimat Cmin ↑102 % (↑77 %
Your doctor will evaluate how severe yourliver disease is before deciding whether you can take Atazanavir Krka - if you are taking any of these medicines: see also Other medicines and Atazanavir Krka - rifampicin (an antibiotic used to treat tuberculosis) - astemizole or terfenadine (commonly used to treat allergy symptoms, these medicines may be available without prescription); cisapride (used to treat gastric reflux, sometimes called heartburn); pimozide (used to treat schizophrenia); quinidine or bepridil (used to correct heart rhythm); ergotamine, dihydroergotamine, ergonovine, methylergonovine (used to treat headaches); and alfuzosin (used to treat enlarged prostatic gland) - quetiapine (used to treat schizophrenia, bipolar disorder and major depressive disorder), lurasidone (used to treat schizophrenia) 
- če jemljete katero od naslednjih zdravil: glejte tudi Druga zdravila in zdravilo Atazanavir Krka - rifampicin (antibiotik, s katerim zdravimo tuberkulozo), - astemizol ali terfenadin (z njima zdravimo simptome alergije in ju ponekod dobimo brez recepta); cisaprid (zdravilo za zdravljenje refluksa želodčne vsebine ali zgage); pimozid (zdravilo za zdravljenje shizofrenije); kinidin ali bepridil (zdravili za uravnavanje srčnega ritma); ergotamin, dihidroergotamin, ergonovin, metilergonovin (zdravila za zdravljenje glavobolov); alfuzosin (uporabljamo ga za zdravljenje povečane prostate), - kvetiapin (uporabljamo ga za zdravljenje shizofrenije, bipolarne motnje in velike depresije);lurasidon (uporabljamo ga za zdravljenje shizofrenije),
- in patients with at least one functional CYP2C19 allele, close clinical monitoring for a loss of both voriconazole (clinical signs) and atazanavir (virologic response) efficacy is recommended. 
CYP2C19 se priporoča skrben klinični nadzor glede izgube učinkovitosti tako vorikonazola (klinični znaki) kot atazanavirja
* When compared to atazanavir 300 mg once daily with ritonavir 100 mg once daily and tenofovir disoproxil fumarate 300 mg all as a single dose with food. 
* V primerjavi z uporabo atazanavirja v odmerku 300 mg enkrat na dan, ritonavirja v odmerku 100 mg enkrat na dan in dizoproksiltenofovirjevega fumarata v odmerku 300 mg, vse v obliki enkratnega odmerka skupaj s hrano.